Short article: Absence of serological rheumatoid arthritis biomarkers in inflammatory bowel disease patients with arthropathies
- 1 March 2017
- journal article
- research article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 29 (3) , 345-348
Abstract
Objective: Biomarkers that are associated with future progression to rheumatoid arthritis (RA) and joint destruction have been discovered previously in patients with arthralgia. The present study examined these RA biomarkers in inflammatory bowel disease (IBD) patients with arthropathies. Patients and methods: Sera from 155 IBD patients with and 99 IBD patients without arthropathies were analyzed for immunoglobulin (Ig) M rheumatoid factor (RF), IgA-RF, anti-cyclic citrullinated peptide 2, anti-cyclic citrullinated peptide 3.1, and anti-carbamylated protein antibody positivity using enzyme-linked immunosorbent assays. The prevalence of the autoantibodies in the IBD patients was compared with the prevalence in RA patients. Results: No differences were found in biomarker positivity between IBD patients with and without arthropathies. Significantly more biomarker positivity (P<0.001) was observed in RA patients compared with IBD patients with arthropathies. Also, smoking turned out to be significantly associated with positivity for IgM-RF or IgA-RF. Conclusion: Our findings suggest that there is no apparent clinical value in the detection of RA biomarkers in serum of IBD patients to help identify arthropathies.Keywords
This publication has 20 references indexed in Scilit:
- Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammationAnnals of the Rheumatic Diseases, 2016
- Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologiesAutoimmunity Reviews, 2014
- Rheumatoid Factors: Clinical ApplicationsDisease Markers, 2013
- Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damageProceedings of the National Academy of Sciences, 2011
- Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort studyAnnals of the Rheumatic Diseases, 2010
- A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritisClinical Rheumatology, 2008
- Autoantibodies to cyclic citrullinated peptide 2 (CCP2) are superior to other potential diagnostic biomarkers for predicting rheumatoid arthritis in early undifferentiated arthritisClinical Rheumatology, 2007
- The benefits of early treatment in rheumatoid arthritis: Confounding by indication, and the issue of timingArthritis & Rheumatism, 2003
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- Severe functional declines, work disability, and increased mortality in seventy‐five rheumatoid arthritis patients studied over nine yearsArthritis & Rheumatism, 1984